Market Access News | pharmaphorum

News

NICE changes stance on Genmab's cervical cancer drug

After saying it couldn't recommend Genmab's cervical cancer therapy Tivdak for use by the NHS, reimbursement authority NICE has had a change of heart.

News

Bayer gets swift review for Kerendia in type 1 diabetes

FDA starts a priority review of Bayer's Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies.

News

European study shows inequality in access to new medicines

Trade organisation EFPIA says disparities in access to new medicines in Europe may be exacerbated by the US's Most-Favoured Nation (MFN) policy.

News

SCOTUS won't hear pharma's IRA complaints

The US Supreme Court has refused to consider lawsuits from pharma groups challenging Medicare's drug pricing negotiation powers.

News

AZ gets first okay for new hypertension drug baxdrostat

AstraZeneca is the first company to get FDA approval for an aldosterone synthase inhibitor for hypertension, ahead of rival Mineralys.

News

After refusing to resign, CDER head Høeg is fired

The turmoil at the FDA continues with the news that Tracy Beth Høeg has been fired as acting head of CDER, to be replaced by Michael Davis.

NICE changes stance on Genmab's cervical cancer drug

Bayer gets swift review for Kerendia in type 1 diabetes

European study shows inequality in access to new medicines

SCOTUS won't hear pharma's IRA complaints

AZ gets first okay for new hypertension drug baxdrostat

After refusing to resign, CDER head Høeg is fired

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks